Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Chronic Immune Activation in HIV-infected Malian Women
NCT02448238 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2017-06-14
Summary
The composition of the intestinal bacterial flora effects gut immunologic function and intestinal barrier integrity. HIV infection impairs gut immune and epithelial function resulting in an altered gut bacterial flora and "leakage" of gut bacterial products into the bloodstream. These bacterial products can overstimulate the immune system leading to increased inflammation and HIV disease progression. The investigators will investigate whether oral supplementation of certain beneficial "probiotic" bacteria may attenuate these processes in HIV infected women in Mali, Africa.
This is a single arm study to evaluate the effect of 12 weeks of combination oral probiotic supplementation (VSL#3, Sigma-Tau Pharmaceuticals - containing 9 × 1011 bacteria of 8 species: S. thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, and Lactobacillus bulgaricus) on plasma biomarkers of immune cell activation, and inflammation. The study population will be 50 chronically HIV-infected but generally healthy, non-pregnant, Malian women subjects with CD4+ T-cell count ≥ 350 cells/mm3 who are not receiving antiretroviral therapy. Blood plasma/serum and fecal sampling will occur at baseline, 4, and 12 week as well as at 24 weeks. At these time points, probiotic will be dispensed, a medical history will be obtained, and adherence will be assessed. Prior to study entry, subjects will have eligibility and safety labs will be obtained and detailed baseline medical and symptom histories, demographics, weight, and stool frequency information will be recorded. A stress assessment questionnaire will be completed at baseline and week 12 to determine the effect of this intervention on stress levels.
The primary study outcome is to assess change (baseline to 12 week) in plasma soluble CD14 (a marker of monocyte response to bacterial endotoxin which has been associated with mortality) with study probiotic. Other outcomes will include assessing change (baseline to 12 week) in plasma interleukin-6, soluble CD163 (another monocyte activation marker), d-dimer (a marker of coagulopathy), intestinal fatty acid binding protein (a marker of gut epithelial cell injury) and fecal calprotectin (a marker of gut inflammation), as well as CD4+ T-cell counts, self reported stool quality (using the Bristol Stool Scale), safety and tolerability of the VSL#3 probiotic, and level of stress.
Conditions
Interventions
- OTHER
-
VSL#3® probiotic
Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special "canari", a commonly used earthenware water container also containing sand that works on the principal of "trans-evaporation" to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator
Sponsors & Collaborators
-
Bill and Melinda Gates Foundation
collaborator OTHER -
Virginia Commonwealth University
lead OTHER
Principal Investigators
-
Daniel E Nixon, DO, PhD · Virginia Commonwealth University, USA
-
Saba Masho, MD, MPH · Virginia Commonwealth University, USA
-
Susan Kornstein, MD · Virginia Commonwealth University, USA
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-05-31
- Primary Completion
- 2016-03-31
- Completion
- 2016-03-31
Countries
- Mali
Study Locations
More Related Trials
-
Probiotic Visbiome for Inflammation and Translocation in HIV Ι
NCT02441244 ·Status: TERMINATED ·Phase: PHASE2
-
Probiotic Visbiome for Inflammation and Translocation in HIV II
NCT02441231 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults
NCT03220724 ·Status: COMPLETED ·Phase: PHASE1
-
Experimental Pneumococcal Carriage in People Living With HIV
NCT05698225 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
NCT00000857 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
NCT02390466 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
NCT00623259 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
NCT03409276 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
NCT00061243 ·Status: UNKNOWN ·Phase: PHASE1
-
Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.
NCT00148824 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Vaccination Before HIV Treatment Interruption
NCT00212888 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
NCT01783977 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating Vaccine in Adults With HIV
NCT00195312 ·Status: TERMINATED ·Phase: PHASE1
-
Synbiotics in Advanced HIV Infection
NCT03009032 ·Status: COMPLETED ·Phase: NA
-
Immune Response to Influenza Vaccine in HIV-Infected Individuals
NCT00069914 ·Status: COMPLETED
-
Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals
NCT03225118 ·Status: COMPLETED
-
Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study
NCT02266992 ·Status: COMPLETED ·Phase: PHASE2
-
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
NCT03560258 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
NCT00000824 ·Status: TERMINATED ·Phase: NA
-
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
NCT00672932 ·Status: COMPLETED ·Phase: NA
-
A Study of the Safety and Antiretroviral Activity of 3BNC117
NCT02588586 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Single IV Administration of P2G12
NCT02923999 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
NCT00001060 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS
NCT01881581 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception
NCT01240811 ·Status: COMPLETED ·Phase: NA